Short answer
Charles River Laboratories (CRL) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 27, 2026. Quarterly revenue was $1.0B (down 2.7% year over year) with net income of −$1M.
Q2 2026 key financials · XBRL
- Revenue
- $1.0B
- −2.7% YoY · +0.8% QoQ
- Net income
- −$1M
- −102.8% YoY · +90.0% QoQ
- Operating margin
- 11.9%
- EPS (diluted)
- −$0.04
- −103.8% YoY · +86.7% QoQ
Source: XBRL data from the Charles River Laboratories (CRL) Q2 2026 10-Q on SEC EDGAR. USD.
Charles River Laboratories Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- DSA backlog $2.0B as of June 27, 2026, versus $1.9B as of December 27, 2025
- Annualized cost savings target approximately $300M by end of 2026
- Restructuring charges $23.1M for quarter and $54.6M for six months
- PathoQuest acquisition: additional 79% equity interest for $67.6M
Risk Factors
- No risk-factors section provided, preventing assessment of changes from the most recent 10-K
- Stock-repurchase authorization reduced to $700.0 million after $100.0 million spent during the quarter
- CEO 10b5-1 plan permits sales of up to 31,314 shares beginning September 1, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Charles River Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.